Tata Chemicals Ltd (TATACHEM)
Outcome of Board Meeting
Q1FY27 results (unaudited):
Standalone:
Revenue 128.1bn +10% y-y (116.9bn)
PAT 34.3bn +12% y-y (30.7bn)
Consolidated:
Revenue 425.5bn +14% y-y (371.9bn)
PAT 6.0bn -81% y-y (31.6bn)
FY26 results (audited):
Standalone:
Revenue 483.1bn +5% y-y (460.7bn approx, inferred)
PAT 60.6bn -39% y-y (99.3bn approx, inferred)
Consolidated:
Revenue 1458.4bn +4% y-y (1400bn approx, inferred)
PAT -171.5bn (loss) vs prior year profit
Dividend: Not stated
Commentary: The Group recorded an impairment charge of 183.7bn towards Goodwill as an exceptional item for FY26. The Company and Group have reorganised reportable segments effective FY27. The standalone and consolidated results include reversals of provisions related to retirals due to harmonisation of salary structures.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 TATACHEM — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add TATACHEM to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Tata Chemicals Ltd
Important.
The summary above is generated automatically from Tata Chemicals Ltd's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.